AAV Vectorization of DSB-mediated Gene Editing Technologies

Author(s): Rachel J. Moser, Matthew L. Hirsch

Journal Name: Current Gene Therapy

Volume 16 , Issue 3 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Recent work both at the bench and the bedside demonstrate zinc-finger nucleases (ZFNs), CRISPR/Cas9, and other programmable site-specific endonuclease technologies are being successfully utilized within and alongside AAV vectors to induce therapeutically relevant levels of directed gene editing within the human chromosome. Studies from past decades acknowledge that AAV vector genomes are enhanced substrates for homology-directed repair in the presence or absence of targeted DNA damage within the host genome. Additionally, AAV vectors are currently the most efficient format for in vivo gene delivery with no vector related complications in >100 clinical trials for diverse diseases. At the same time, advancements in the design of custom-engineered site-specific endonucleases and the utilization of elucidated endonuclease formats have resulted in efficient and facile genetic engineering for basic science and for clinical therapies. AAV vectors and gene editing technologies are an obvious marriage, using AAV for the delivery of repair substrate and/or a gene encoding a designer endonuclease; however, while efficient delivery and enhanced gene targeting by vector genomes are advantageous, other attributes of AAV vectors are less desirable for gene editing technologies. This review summarizes the various roles that AAV vectors play in gene editing technologies and provides insight into its trending applications for the treatment of genetic diseases.

Keywords: AAV Vectorization, DSB, CRISPR/Cas9, DNA, ZFNs.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 16 June, 2016
Page: [207 - 219]
Pages: 13
DOI: 10.2174/1566523216666160602213738
Price: $65

Article Metrics

PDF: 101